Kiniksa pharmaceuticals, ltd. (KNSA)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Sep'17Jun'17
Operating expenses:
Research and development

20,901

22,886

22,014

30,848

59,253

36,123

20,644

17,200

12,630

14,008

9,272

General and administrative

8,486

9,695

8,432

8,441

8,394

8,011

5,515

4,327

3,710

2,241

2,120

Total operating expenses

29,387

32,581

30,446

39,289

67,647

44,134

26,159

21,527

16,340

16,249

11,392

Loss from operations

-29,387

-32,581

-30,446

-39,289

-67,647

-44,134

-26,159

-21,527

-16,340

-16,249

-11,392

Interest income

789

1,130

1,386

1,724

1,809

1,726

1,622

1,066

305

169

153

Loss before benefit for income taxes

-28,598

-31,451

-29,060

-37,565

-65,838

-42,408

-24,537

-20,461

-16,035

-16,080

-11,239

Benefit for income taxes

-2,179

346

-2,002

-374

-17

172

-131

-202

-53

-51

-36

Net loss

-26,419

-31,797

-27,058

-37,191

-65,821

-42,580

-24,406

-20,259

-15,982

-16,029

-11,203

Net loss per share attributable to common shareholders—basic and diluted

-0.48

-0.55

-0.49

-0.68

-1.27

4.58

-0.51

-1.11

-6.45

-8.25

-6.69

Weighted average common shares outstanding—basic and diluted

55,322

55,132

54,831

54,475

51,758

49,198

48,183

18,328

2,478

1,942

1,673

Comprehensive loss:
Net loss

-26,419

-31,797

-27,058

-37,191

-65,821

-42,580

-24,406

-20,259

-15,982

-

-

Other comprehensive income:
Unrealized gain on short-term investments and currency translation adjustments, net of tax

207

-29

-39

93

12

-

-62

7

-

-

-

Total other comprehensive income

207

-29

-39

93

12

-

-

-

-

-

-

Total comprehensive loss

-26,212

-31,826

-27,097

-37,098

-65,809

-42,584

-24,406

-20,259

-15,982

-

-